FDA Initiates Class II Recall of KABANA SKIN CARE's GreenScreen Zinc Oxide Sunscreen Over cGMP Violations
KABANA SKIN CARE has initiated a Class II recall for 174 tubes of its GreenScreen Zinc Oxide Sunscreen (NDC: 73369-0001-1) from its Louisville, CO facility, citing cGMP deviations. This voluntary action, affecting lots 405-002 and 405-003 distributed across NJ, FL, and MI, underscores critical quality control lapses. Procurement and regulatory teams must scrutinize supplier cGMP compliance to mitigate supply chain risks and ensure product integrity for consumer safety.
FDA Initiates Class II Recall of KABANA SKIN CARE's GreenScreen Zinc Oxide Sunscreen Due to cGMP Deviations
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by KABANA SKIN CARE for its GreenScreen, kabana organic skincare, Bread Spectrum UVA & UVB, Zinc Oxide Sunscreen as Class II. This action, identified by recall number D-0514-2025, addresses significant deviations from current Good Manufacturing Practices (cGMP) at the firm's Louisville, CO facility, located at 685 S Arthur Ave Unit 9b, 80027-3141. The affected product is specifically the Original, SPF 32, Totally Green personal care, Zinc Oxide USP 25% formulation, supplied in a 3.4 FL OZ/115 G Tube, bearing NDC: 73369-0001-1. This recall, initiated on March 12, 2025, impacts 174 tubes across two specific production lots: 405-002 and 405-003. For procurement directors, this event underscores the critical importance of rigorous supplier qualification and ongoing audit programs, even for smaller manufacturers of over-the-counter (OTC) drug products. The presence of cGMP deviations, regardless of the product's perceived risk profile, can lead to market withdrawals, significant logistical burdens, and potential liabilities. Supply chain VPs must recognize that reliance on suppliers with inadequate quality systems introduces direct risk to product availability and brand reputation across distribution channels.
Commercial Imperatives: Mitigating Supply Chain Risk from cGMP Non-Compliance in OTC Topical Formulations
The cGMP deviations identified at KABANA SKIN CARE for their Zinc Oxide Sunscreen highlight a pervasive challenge within the topical drug and cosmetic sectors. While the specific nature of the cGMP lapses is not detailed in the recall notice, such deviations can range from inadequate raw material testing and process controls to insufficient finished product quality assurance. For business development executives exploring partnerships or expanding product lines involving active pharmaceutical ingredients (APIs) like Zinc Oxide USP 25%, this incident serves as a stark reminder of the foundational role of quality systems. Any compromise in cGMP adherence directly impacts product efficacy, safety, and regulatory standing. Regulatory affairs heads must ensure that their internal quality management systems are robust enough to detect and address potential supplier non-compliance before it escalates to a recall event. The distribution pattern of the recalled product, spanning New Jersey, Florida, and Michigan, indicates a regional market presence, yet the principles of cGMP compliance are universal. This event necessitates a re-evaluation of supplier contracts to include stringent quality clauses and performance metrics, mitigating the commercial exposure to similar quality failures in the broader supply chain for topical formulations.
Post-Recall Remediation and Sustaining Regulatory Compliance for Consumer Health Products
Following a Class II recall due to cGMP deviations, KABANA SKIN CARE is obligated to conduct a thorough root cause analysis and implement comprehensive corrective and preventive actions (CAPA). This process typically involves identifying the specific manufacturing or quality control failures, rectifying them, and verifying the effectiveness of these changes to prevent recurrence. For regulatory affairs teams, this incident reinforces the FDA's unwavering expectation for continuous compliance, even for voluntary recalls. The firm's ability to effectively manage this recall, including communication with affected distributors and consumers, and to demonstrate robust remediation efforts will be critical in avoiding further regulatory scrutiny, such as potential Warning Letters or an escalation in enforcement actions. Supply chain VPs should review their own recall readiness protocols, ensuring efficient product traceability from manufacturing to end-user, especially for products distributed across multiple states like the GreenScreen sunscreen. The financial and reputational costs associated with such recalls, including lost sales and potential consumer distrust, underscore the strategic imperative of proactive quality management and a culture of compliance throughout the entire product lifecycle for consumer health products.